Welcome to our dedicated page for MBX Biosciences SEC filings (Ticker: MBX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The MBX Biosciences, Inc. (Nasdaq: MBX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a clinical-stage biopharmaceutical company and emerging growth company, MBX uses filings such as Forms S-1, 10-K, 10-Q, and 8-K to describe its Precision Endocrine Peptide™ (PEP™) platform, clinical programs, risk factors, and capital-raising activities.
In its S-1 registration statement, MBX outlines its focus on novel precision peptide therapies for endocrine and metabolic disorders and details key product candidates, including canvuparatide (MBX 2109) for chronic hypoparathyroidism, imapextide (MBX 1416) for post-bariatric hypoglycemia, and MBX 4291 for obesity. Subsequent 8-K filings report material events such as topline results from the Phase 2 Avail™ trial of canvuparatide, initiation of the Phase 1 trial of MBX 4291, public equity offerings, and changes in board and committee roles.
Through this page, users can review MBX’s periodic financial reports, which discuss research and development spending, cash and marketable securities, and expectations about funding operations, as well as prospectus materials that describe intended uses of offering proceeds. Form 8-K filings also summarize key clinical data, trial designs, and future development plans for the company’s programs.
Stock Titan enhances these filings with AI-powered summaries that highlight the main points of lengthy documents, helping readers quickly understand topics such as clinical results, financing terms, and governance updates. Real-time updates from EDGAR, along with structured access to material event reports and registration statements, make this page a central resource for analyzing MBX’s regulatory and financial disclosures.
MBX Biosciences director Edward T. Mathers received a new stock option grant covering 12,500 shares of common stock. The option has an exercise price of $30.91 per share and expires on June 4, 2036. Following this grant, he holds 12,500 stock option rights directly.
The grant vests in full on the earlier of the one-year anniversary of the grant date or the date of the company’s next annual meeting of stockholders, as long as he continues serving as a non-employee director.
MBX Biosciences director Ora H. Pescovitz received a grant of stock options, reflecting equity-based compensation rather than an open-market trade. The award covers 12,500 options to buy common stock at an exercise price of $30.91 per share, expiring on June 4, 2036.
According to the terms, the grant will vest in full on the earlier of the one-year anniversary of the grant date or the company’s next annual stockholder meeting, subject to her continued service as a non-employee director. Following this filing, she also holds 24,329 shares of common stock directly.
MBX Biosciences, Inc. director and ten percent owner Patrick J. Heron received a grant of stock options covering 12,500 shares of common stock. The options have an exercise price of $30.91 per share and expire on June 4, 2036.
The grant will vest in full on the earlier of the one-year anniversary of the grant date or the date of the company’s next annual meeting of stockholders, as long as the non-employee director continues to provide services. This is a compensation-related award rather than an open-market share purchase or sale.
MBX Biosciences, Inc. director Laurie Stelzer received a grant of stock options covering 12,500 shares of common stock. The options have an exercise price of $30.91 per share and expire on June 4, 2036.
According to the terms, the grant will vest in full on the earlier of the one-year anniversary of the June 4, 2026 grant date or the date of the company’s next annual meeting of stockholders, as long as Stelzer continues to serve as a non-employee director. Following this award, Stelzer holds options for 12,500 shares directly.
MBX Biosciences director Steven L. Hoerter received a grant of stock options covering 12,500 shares of common stock. The options have an exercise price of $30.9100 per share and expire on June 4, 2036. According to the footnotes, the grant will vest in full on the earlier of the one-year anniversary of the grant date or the date of the company’s next annual meeting of stockholders, as long as he continues serving as a non-employee director.
After these transactions, Hoerter is reported as holding 11,938 shares of common stock directly and 20,000 shares indirectly through the Steven L Hoerter Revocable Trust dated November 2, 2018, where he serves as trustee and disclaims beneficial ownership except for any pecuniary interest.
MBX Biosciences director Steven Ryder received a grant of stock options covering 12,500 shares of common stock. The options have an exercise price of $30.91 per share and were awarded at no cost as a compensation grant.
The award vests in full on the earlier of the one-year anniversary of the grant date or the company’s next annual stockholder meeting, as long as Ryder continues serving as a non-employee director. After this grant, he holds options for 12,500 underlying shares, which expire on June 4, 2036.
MBX Biosciences, Inc. director Tiba Aynechi received a grant of stock options covering 12,500 shares of common stock as equity compensation. The options have an exercise price of $30.91 per share and expire on June 4, 2036. The grant will vest in full on the earlier of the one-year anniversary of the grant date or the company’s next annual meeting of stockholders, as long as the non-employee director continues to serve.
MBX Biosciences, Inc. reported the results of its 2026 annual meeting of stockholders held on June 4, 2026. Stockholders elected two Class II directors, Patrick J. Heron and Edward T. Mathers, to serve terms ending at the 2029 annual meeting.
As of the April 10, 2026 record date, there were 47,570,485 outstanding shares of common stock. Heron received 35,007,623 votes for and 4,579,129 withheld, while Mathers received 31,983,223 votes for and 7,603,529 withheld, with 4,130,833 broker non-votes for each. Stockholders also ratified Ernst & Young LLP as independent registered public accounting firm for the year ending December 31, 2026, with 43,713,693 votes for, 1,946 against and 1,946 abstentions.
MBX insider sale notice: A Form 144 filing lists an intended sale of 15,000 shares of Common Stock on 05/13/2026 through Fidelity Brokerage Services LLC on NASDAQ. The excerpt also lists multiple recent dispositions by Richard B. Bartram totaling large block sales from 03/16/2026 through 05/11/2026.
MBX Biosciences Chief Medical Officer Salomon Azoulay reported an exercise-and-sell transaction in company stock. On 2026-05-08, he exercised options to acquire a total of 70,003 shares of common stock at strike prices of $16.00 and $10.46 per share, then sold 70,003 shares in open-market transactions.
The sales occurred at weighted average prices of $38.30 and $38.38 per share, with individual trades executed between $35.00 and $41.26, under an approved Rule 10b5-1 trading plan adopted on January 27, 2026. Following these transactions, Azoulay directly holds 14,769 common shares.
He also retains stock options, including grants that had 30,008 and 194,540 options outstanding after the reported exercises, subject to vesting schedules that began vesting 25% on June 24, 2025 and September 12, 2025, with the remaining 75% vesting in 36 monthly installments.